HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver.

Abstract
SR 4233 or WIN 59075 (3-amino-1,2,4-benzotriazine-1,4-dioxide) is a novel and highly selective hypoxic cell cytotoxin requiring reductive bioactivation for its impressive antitumour effects. Expression of appropriate reductases will contribute to therapeutic selectivity. Here we provide more detailed information on the role of cytochrome P450 and cytochrome P450 reductase in SR 4233 reduction by mouse liver microsomes. Reduction of SR 4233 to the mono-N-oxide SR 4317 (3-amino-1,2,4-benzotriazine-1-oxide) is NADPH, enzyme and hypoxia dependent. An inhibitory antibody to cytochrome P450 reductase decreased the microsomal SR 4233 reduction rate by around 20%. Moreover, studies with purified rat cytochrome P450 reductase showed unequivocally that this enzyme was able to catalyse SR 4233 reduction at a rate of 20-30% of that for microsomes with equivalent P450 reductase activity. Exposure to the specific cytochrome P450 inhibitor carbon monoxide (CO) inhibited microsomal reduction by around 70% and CO plus reductase antibody blocked essentially all activity. Additional confirmation of cytochrome P450 involvement was provided by the use of other P450 ligands: beta-diethylaminoethyl diphenylpropylacetate hydrochloride gave a slight stimulation while aminopyrine, n-octylamine and 2,4-dichloro-6-phenylphenoxyethylamine were inhibitory. Induction of SR 4233 reduction was seen with phenobarbitone, pregnenalone-16-alpha-carbonitrile and beta-napthoflavone, suggesting that cytochrome P450 subfamilies IIB, IIC and IIIA may be involved. Since cytochrome P450 and P450 reductase catalyse roughly 70 and 30%, of mouse liver microsomal SR 4233 reduction respectively, we propose that expression of these and other reductases in normal and tumour tissue is likely to be a major factor governing the toxicity and antitumour activity of the drug.
AuthorsM I Walton, C R Wolf, P Workman
JournalBiochemical pharmacology (Biochem Pharmacol) Vol. 44 Issue 2 Pg. 251-9 (Jul 22 1992) ISSN: 0006-2952 [Print] England
PMID1642640 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Triazines
  • Tirapazamine
  • 3-amino-1,2,4-benzotriazine
  • 3-amino-1,2,4-benzotriazine-1-oxide
  • Carbon Monoxide
  • Cytochrome P-450 Enzyme System
  • NADPH-Ferrihemoprotein Reductase
  • Phenobarbital
Topics
  • Animals
  • Biotransformation
  • Carbon Monoxide (pharmacology)
  • Cell Hypoxia
  • Cell Survival
  • Cytochrome P-450 Enzyme System (metabolism)
  • Male
  • Mice
  • Mice, Inbred C3H
  • Microsomes, Liver (drug effects, enzymology)
  • NADPH-Ferrihemoprotein Reductase (antagonists & inhibitors, immunology, metabolism)
  • Phenobarbital
  • Tirapazamine
  • Triazines (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: